摘要
For many different cancers,the advent of immunotherapy(IT)treatments,in particular immune checkpoint inhibitors,aimed at reviving the immune response against cancer cells,has led to a great improvement in terms of clinical benefit.Despite the success of IT,even in advanced metastatic cancers,some patients still fail to respond for reasons yet unclear(1,2).Yu et al.in an issue of Nature Medicine.
